RxDoctor Payments DataLook up a doctor →

Tyler Hobbs

Primary Care · Provo, UTNPI 1528542644

Payments from drug & device makers

$14,846in general payments, 2019–2025

Across 928 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • UCB, Inc.$2K
  • AbbVie$2K
  • Johnson & Johnson$2K
  • Pfizer$843
  • Novartis$804
  • plus $4K from 21 others

What the payments were for

  • Food & beverage$14,68499%
  • Education$1621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,846 in reported general payments places this provider in the 95th percentile of 60 primary care providers in Utah.

See all primary care providers in Utah

Medicare billing

Part B allowed, 2024
$2,560,553
Medicare patients
342
Services billed
397,848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib36$262,933
Humira(Cf) PenAdalimumab37$259,093
Enbrel SureclickEtanercept19$164,665
EnbrelEtanercept12$91,000
Hydroxychloroquine Sulfate462$22,399
MethotrexateMethotrexate Sodium384$11,283
Celecoxib249$10,509
Diclofenac Sodium130$4,298
Gabapentin153$3,269
Leflunomide56$2,750
Omeprazole192$2,385
Duloxetine Hcl67$1,615
Methylprednisolone72$1,446
Tramadol Hcl167$1,427
Potassium Chloride33$1,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,832$262,93336 claims
AmgenEnbrel$3,315$91,00012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 60 primary care providers in Utah.

Other primary care in Provo

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →